Inhibikase Therapeutics (IKT) Corporate presentation summary

Disease overview and unmet need

• Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease with a ~30% five-year mortality rate, reduced quality of life, and high economic burden.

• Current market is $8.3B, dominated by vasodilators that do not address the underlying disease cause.

• Only one approved anti-proliferative agent exists, highlighting a significant unmet medical need.

Scientific rationale and mechanism

• PAH is driven by uncontrolled proliferation of vascular cells, leading to vascular remodeling and right heart failure.

• Imatinib, a tyrosine kinase inhibitor (TKI), targets PDGFR and c-kit, blocking cell signaling that drives vascular remodeling.

• Animal models show imatinib reverses vascular remodeling, reduces right ventricular pressure, and improves survival.

Clinical data and product profile

• Imatinib demonstrated statistically significant improvements in 6-minute walk distance (6MWD) and pulmonary vascular resistance (PVR) in Phase 3 IMPRES, but high discontinuation rates due to GI side effects prevented approval.

• Patients able to sustain a 400mg dose showed a 45-meter placebo-adjusted improvement in 6MWD.

• Contemporary studies confirm dose-dependent efficacy and disease modification, with improved tolerability at lower doses.